MEIP - MEI Pharma, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

MEI Pharma, Inc.

3611 Valley Centre Drive
Suite 500
San Diego, CA 92130
United States

IndustryDrug Manufacturers - Other
Full Time Employees25

Key Executives

Dr. Daniel P. Gold Ph.D.Pres, CEO & Director841.8kN/A63
Mr. Brian G. Drazba CPASec. & CFON/AN/A56
Mr. David M. Urso Esq., J.D.Sr. VP of Corp. Devel. and Gen. Counsel501.36kN/A53
Dr. Robert D. Mass M.D.Chief Medical Officer242.54kN/A63
Dr. Karen E. Potts Ph.D.Sr. VP of Regulatory AffairsN/AN/A54
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacturing, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.

Corporate Governance

MEI Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.